Kellie Machlus

Publications

1. CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias. bioRxiv. 2024 Dec 30. View Abstract
2. Inhibition of RhoA-mediated secretory autophagy in megakaryocytes mitigates myelofibrosis in mice. bioRxiv. 2024 Dec 05. View Abstract
3. Targeting cargo to an unconventional secretory system within megakaryocytes allows the release of transgenic proteins from platelets. J Thromb Haemost. 2024 Nov; 22(11):3235-3248. View Abstract
4. The Use of Clot Strength as a Predictor of Thrombosis in Peripheral Artery Disease. Ann Vasc Surg. 2024 Dec; 109:273-283. View Abstract
5. Evidence for a cytoplasmic proplatelet promoting factor that triggers platelet production. Haematologica. 2024 07 01; 109(7):2341-2345. View Abstract
6. Cell cycle-dependent centrosome clustering precedes proplatelet formation. Sci Adv. 2024 Jun 21; 10(25):eadl6153. View Abstract
7. SARS-CoV-2 infection modifies the transcriptome of the megakaryocytes in the bone marrow. Blood Adv. 2024 06 11; 8(11):2777-2789. View Abstract
8. The Impact of Sex on Antiplatelet and Anticoagulant Thromboprophylaxis in Patients With Peripheral Artery Disease Post-revascularization. Ann Surg. 2024 Sep 01; 280(3):463-472. View Abstract
9. Dynamic actin/septin network in megakaryocytes coordinates proplatelet elaboration. Haematologica. 2024 03 01; 109(3):915-928. View Abstract
10. The impact of sex on platelet responses to aspirin in patients with peripheral artery disease. Am J Hematol. 2024 Apr; 99 Suppl 1:S6-S12. View Abstract
11. The bone marrow is the primary site of thrombopoiesis. Blood. 2024 01 18; 143(3):272-278. View Abstract
12. The many faces of the megakaryocytes and their biological implications. Curr Opin Hematol. 2024 01 01; 31(1):1-5. View Abstract
13. Peripheral megakaryocytes sound the alarm in COVID-19. Blood Adv. 2023 08 08; 7(15):4197-4199. View Abstract
14. Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36. Nat Cardiovasc Res. 2023 Aug; 2(8):746-763. View Abstract
15. Spatial transcriptomics of murine bone marrow megakaryocytes at single-cell resolution. Res Pract Thromb Haemost. 2023 May; 7(4):100158. View Abstract
16. Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36. bioRxiv. 2023 Feb 12. View Abstract
17. Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies. Cancer Discov. 2023 02 06; 13(2):364-385. View Abstract
18. The origin of the megakaryocyte. Nat Cardiovasc Res. 2022 Jul; 1(7):593-594. View Abstract
19. The pathobiology of platelet and megakaryocyte extracellular vesicles: A (c)lot has changed. J Thromb Haemost. 2022 07; 20(7):1550-1558. View Abstract
20. Beyond the thrombus: Platelet-inspired nanomedicine approaches in inflammation, immune response, and cancer. J Thromb Haemost. 2022 07; 20(7):1523-1534. View Abstract
21. Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Res Pract Thromb Haemost. 2021 Jul; 5(5):e12532. View Abstract
22. Fluorescence artifact correction in the thrombin generation assay: Necessity for correction algorithms in procoagulant samples. Res Pract Thromb Haemost. 2021 Mar; 5(3):447-455. View Abstract
23. Location is everything when it comes to megakaryocyte function. J Clin Invest. 2021 01 04; 131(1). View Abstract
24. Fc?RIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus. Blood. 2020 12 17; 136(25):2933-2945. View Abstract
25. Novel gene variants in patients with platelet-based bleeding using combined exome sequencing and RNAseq murine expression data. J Thromb Haemost. 2021 01; 19(1):262-268. View Abstract
26. Platelet Extracellular Vesicles: Beyond the Blood. Arterioscler Thromb Vasc Biol. 2021 01; 41(1):87-96. View Abstract
27. Comparative Analysis of Thrombin Calibration Algorithms and Correction for Thrombin-a2macroglobulin Activity. J Clin Med. 2020 Sep 24; 9(10). View Abstract
28. In vitro megakaryocyte culture from human bone marrow aspirates as a research and diagnostic tool. Platelets. 2021 Oct 03; 32(7):928-935. View Abstract
29. High-content, label-free analysis of proplatelet production from megakaryocytes. J Thromb Haemost. 2020 10; 18(10):2701-2711. View Abstract
30. Fc?RIIA expression aggravates nephritis and increases platelet activation in systemic lupus erythematosus in mice. Blood. 2020 Aug 07. View Abstract
31. Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation. Blood Adv. 2020 07 14; 4(13):3011-3023. View Abstract
32. Venous thromboembolism research priorities: A scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis. Res Pract Thromb Haemost. 2020 Jul; 4(5):714-721. View Abstract
33. Venous Thromboembolism Research Priorities: A Scientific Statement From the American Heart Association and the International Society on Thrombosis and Haemostasis. Circulation. 2020 08 11; 142(6):e85-e94. View Abstract
34. Blood and Bone: The quarantine chronicles. Res Pract Thromb Haemost. 2020 Jul; 4(5):727-730. View Abstract
35. Teamwork makes the dream work in thrombopoiesis. Blood. 2019 09 05; 134(10):791-792. View Abstract
36. Modulation of megakaryopoiesis and platelet production during inflammation. Thromb Res. 2019 Jul; 179:114-120. View Abstract
37. New Insights Into the Differentiation of Megakaryocytes From Hematopoietic Progenitors. Arterioscler Thromb Vasc Biol. 2019 07; 39(7):1288-1300. View Abstract
38. Megakaryocyte emperipolesis mediates membrane transfer from intracytoplasmic neutrophils to platelets. Elife. 2019 05 01; 8. View Abstract
39. Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis. Blood Adv. 2019 01 22; 3(2):198-211. View Abstract
40. Tyrosyl-tRNA synthetase drives megakaryopoiesis independently of thrombopoietin signaling. J Thromb Haemost. 2019 04; 17(4):564-566. View Abstract
41. Megakaryocyte modification of platelets in thrombocytopenia. Curr Opin Hematol. 2018 09; 25(5):410-415. View Abstract
42. In vitro culture of murine megakaryocytes from fetal liver-derived hematopoietic stem cells. Platelets. 2018 Sep; 29(6):583-588. View Abstract
43. Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity. J Thromb Haemost. 2018 09; 16(9):1817-1829. View Abstract
44. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proc Natl Acad Sci U S A. 2018 02 13; 115(7):E1550-E1559. View Abstract
45. Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets. Blood Adv. 2017 Sep 12; 1(20):1773-1785. View Abstract
46. Deletion of the Arp2/3 complex in megakaryocytes leads to microthrombocytopenia in mice. Blood Adv. 2017 Aug 08; 1(18):1398-1408. View Abstract
47. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017 08 31; 130(9):1132-1143. View Abstract
48. RBCs pin platelets against the (thrombus) wall. Blood. 2017 05 04; 129(18):2460-2461. View Abstract
49. Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis. Arterioscler Thromb Vasc Biol. 2017 04; 37(4):664-674. View Abstract
50. Synthesis and dephosphorylation of MARCKS in the late stages of megakaryocyte maturation drive proplatelet formation. Blood. 2016 Mar 17; 127(11):1468-80. View Abstract
51. CCL5 derived from platelets increases megakaryocyte proplatelet formation. Blood. 2016 Feb 18; 127(7):921-6. View Abstract
52. Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice. Thromb Haemost. 2015 Nov 25; 114(6):1218-29. View Abstract
53. Inducible Gata1 suppression expands megakaryocyte-erythroid progenitors from embryonic stem cells. J Clin Invest. 2015 Jun; 125(6):2369-74. View Abstract
54. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Reports. 2014 Nov 11; 3(5):817-31. View Abstract
55. Platelet bioreactor-on-a-chip. Blood. 2014 Sep 18; 124(12):1857-67. View Abstract
56. Proteasome function is required for platelet production. J Clin Invest. 2014 Sep; 124(9):3757-66. View Abstract
57. Platelet bioreactor-on-a-chip. Blood. 2014 Jul 21. View Abstract
58. Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol. 2014 Apr; 165(2):227-36. View Abstract
59. Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood. 2014 Jan 02; 123(1):101-12. View Abstract
60. The incredible journey: From megakaryocyte development to platelet formation. J Cell Biol. 2013 Jun 10; 201(6):785-96. View Abstract
61. Elevated prothrombin promotes venous, but not arterial, thrombosis in mice. Arterioscler Thromb Vasc Biol. 2013 Aug; 33(8):1829-36. View Abstract
62. T granules in human platelets function in TLR9 organization and signaling. J Cell Biol. 2012 Aug 20; 198(4):561-74. View Abstract
63. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth Analg. 2012 Feb; 114(2):275-85. View Abstract
64. Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice. Blood. 2011 Oct 06; 118(14):3960-8. View Abstract
65. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma. Thromb Res. 2011 Dec; 128(6):570-6. View Abstract
66. Update on venous thromboembolism: risk factors, mechanisms, and treatments. Arterioscler Thromb Vasc Biol. 2011 Mar; 31(3):476-8. View Abstract
67. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011 May 05; 117(18):4953-63. View Abstract
68. Smoking out the cause of thrombosis. Arterioscler Thromb Vasc Biol. 2010 Jan; 30(1):7-8. View Abstract
69. Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost. 2009 Nov; 102(5):936-44. View Abstract
70. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res. 2010 Jan; 125(1):90-6. View Abstract
Show All Publications Show Fewer Publications